A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Applied Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 113,900 shares of APLT stock, worth $100,232. This represents 0.0% of its overall portfolio holdings.

Number of Shares
113,900
Previous 91,600 24.34%
Holding current value
$100,232
Previous $427,000 126.7%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.35 - $8.5 $1.21 Million - $2.35 Million
277,030 Added 362.35%
353,483 $3 Million
Q2 2024

Aug 14, 2024

BUY
$4.04 - $6.37 $296,309 - $467,201
73,344 Added 2359.09%
76,453 $357,000
Q1 2024

May 15, 2024

SELL
$2.25 - $7.4 $167,631 - $551,322
-74,503 Reduced 95.99%
3,109 $21,000
Q4 2023

Feb 14, 2024

BUY
$1.84 - $3.35 $142,119 - $258,750
77,239 Added 20707.51%
77,612 $260,000
Q3 2023

Nov 14, 2023

SELL
$1.26 - $2.77 $10,279 - $22,597
-8,158 Reduced 95.63%
373 $0
Q2 2023

Aug 14, 2023

BUY
$0.77 - $1.8 $6,568 - $15,355
8,531 New
8,531 $10,000
Q4 2022

Feb 14, 2023

BUY
$0.54 - $1.12 $201 - $418
374 New
374 $0
Q2 2022

Aug 15, 2022

BUY
$0.76 - $2.64 $47,240 - $164,097
62,158 Added 372.54%
78,843 $75,000
Q1 2022

May 16, 2022

BUY
$1.48 - $6.22 $8,919 - $37,487
6,027 Added 56.55%
16,685 $35,000
Q4 2021

Feb 14, 2022

SELL
$8.77 - $18.29 $21,582 - $45,011
-2,461 Reduced 18.76%
10,658 $95,000
Q2 2021

Aug 16, 2021

BUY
$14.05 - $25.04 $184,321 - $328,499
13,119 New
13,119 $272,000
Q3 2020

Nov 16, 2020

SELL
$19.43 - $35.36 $1.23 Million - $2.24 Million
-63,322 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$29.41 - $51.23 $665,548 - $1.16 Million
22,630 Added 55.61%
63,322 $2.29 Million
Q1 2020

May 15, 2020

BUY
$19.54 - $55.47 $795,121 - $2.26 Million
40,692 New
40,692 $1.33 Million

Others Institutions Holding APLT

About Applied Therapeutics Inc.


  • Ticker APLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,020,700
  • Market Cap $42.3M
  • Description
  • Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...
More about APLT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.